In conclusion the data presented here provides new mechanistic evidence regarding the potential biological effects of AAT augmentation therapy mediated by NFκB inhibition and/or altered miRNA expression that has implications for AAT deficiency and other diseases where AAT augmentation therapy may have relevance. Here, NFKB1 is linked to alpha 1-antitrypsin deficiency.